Official Journal of The Kidney Cancer Association
Volume 16, Number 3 2018
kidney-cancer-journal.com
cabozantinib nivolumab
atezolizumab
bevacizumab
An Edu cational Service for Medical Oncologists, Hematologist-Oncologists, and Urologists
Now in Its 16th Year
axitinib
avelumab
lenvatinib
pembrolizumab
axitinib pembrolizumab
Redefining the
Rationale for IO +
Targeted Therapy
TKI Monotherapy:
When Is It Still
Appropriate?
New Data: the
Landscape of
Adjuvant Therapy
/kidney-cancer-journal.com